Heron Therapeutics to Present Data From Completed Phase 3 MAGIC Study of SUSTOL® at ASCO Breast Cancer Symposium
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/19/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Wells Fargo Downgrades Netflix (NFLX) to Underweight on Engagement Risks, 'We see tougher choices ahead'
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- SanDisk stock rallies on AI optimism and Fed relief
Brean Capital Raises Price Target on Heron Therapeutics (HRTX) Following Positive HTX-011 Results
September 23, 2015 11:00 AM EDTBrean Capital reiterated a Buy rating on Heron Therapeutics (NASDAQ: HRTX), and raised the price target to $55.00 (from $45.00), following announced positive top-line results from HTX-011. Analyst Jonathan Aschoff projects HTX-011 to have a higher price, and drive significant value.
Aschoff commented, "Yesterday, Heron announced positive top-line results from its Phase 2 trial of HTX-011 for the treatment of post-operative pain after bunionectomy. This randomized, placebo-controlled, double-blind, Phase 2 trial evaluated the... More
Heron Therapeutics (HRTX) to Present SUSTOL Data as CINV Prevention at ASCO 2015 Breast Cancer Symposium
September 22, 2015 8:06 AM EDTHeron Therapeutics (NASDAQ: HRTX) announced that data from Herons recently completed MAGIC Study of SUSTOL (granisetron) Injection, extended release, for the prevention of chemotherapy-induced nausea and vomiting (CINV) in patients receiving highly emetogenic chemotherapy (HEC), will be presented at the American Society of Clinical... More
